Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2020-09-22 Major Shareholding Noti…
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change in substantial holding 14 pages 64.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of a substantial holder under the Corporations Act Section 671B. It details changes in voting power and relevant interests of Bank of America Corporation and its related bodies corporate in Opthea Ltd. The document includes specifics about securities transactions, voting rights, and associated agreements. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is lengthy and detailed, not a brief announcement or a report publication notice, and it does not contain financial statements or management commentary. Therefore, the correct classification is MRQ with high confidence.
2020-09-22 English
Change in substantial holding 55 pages 252.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of a substantial shareholder (Bank of America Corporation and related bodies corporate) in Opthea Ltd. The document includes tables of securities held, changes in interests, and associations. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2020-09-21 English
Regulatory Filings 2020
Regulatory Filings
2020-09-16 English
Initial Director's Interest Notice - DS 2 pages 133.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically noting the director's appointment date and securities holdings (nil in this case). This type of document is a report of personal share transactions or interests by company directors. It is not a financial report, regulatory filing, or announcement of a meeting or vote. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short but contains substantive information about director interests, not just an announcement or certification, so it is not RNS or RPA.
2020-09-14 English
Annual Report 2020 72 pages 4.3MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019 – 2020' and contains detailed information about the company's activities, clinical trials, financial year, and future plans. It includes extensive narrative on clinical development, regulatory interactions, and strategic outlook. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the description of an Annual Report (10-K) which covers company activity and full financial performance over a fiscal year. There is no indication that this is merely an announcement or a certification, nor is it a transcript, presentation, or other specific filing type. Therefore, the document is best classified as an Annual Report (10-K).
2020-09-10 English
Appendix 4G and Corporate Governance Statement 2020 22 pages 541.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2020. The document includes references to the corporate governance statement, URLs to governance charters, and notes that the statement is approved by the board. It is not the corporate governance statement itself but a key to disclosures and a verification tool lodged alongside the annual report. The document is not a full annual report, audit report, or management report but a regulatory filing related to governance disclosures. It is a compliance and disclosure document required by the ASX listing rules, fitting the category of Regulatory Filings (RNS).
2020-09-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.